Navigation Links
HCV Patients Survival After Liver Transplantation is Not Improving

For liver transplant recipients without hepatitis C (HCV), survival has improved over time. However, for recipients with HCV, survival has not improved , according to a study in the issue of Liver Transplantation.

HCV-induced liver disease is the most common reason for liver transplantation in the U.S., however, previous studies have shown that these patients do not respond as well to liver transplantation. The difference has become even more striking in recent years, leading some to suggest that survival rates have been decreasing for patients with HCV who have received transplants.

Researchers led by Paul Thuluvath of The Johns Hopkins School of Medicine in Baltimore, MD, sought to study a large sample of the liver transplant population to determine if there has indeed been a decline in survival among HCV patients after adjusting for possible confounding factors.

They gathered data from the United Network for Organ Sharing on all adult liver transplantation performed in the U.S. between January 1991 and October 2001. They included 5,708 HCV patients and 16,116 non-HCV patients and performed multivariate analysis to determine the impact of confounding factors on survival.

The proportion of liver transplant patients with HCV increased dramatically over the study time period, from 16.4 percent in 1991 to 54.7 percent in 2001. However, patients with HCV had a lower 3-year survival (78.5 percent) compared to non-HCV patients (81.7 percent.) For the former group, there was no improvement in survival during the study period, in contrast to the latter group.

"In summary, the survival of patients transplanted with HCV is significantly lower than those without HCV," the authors report. "There has been a statistically significant improvement in patient and graft survival for non-HCV recipients between 1991 and 2001, but for HCV recipients, the survival rate has remained unchanged without any obvious exp lanations."

Another article in the same issue of Liver Transplantation by Luca Belli of Niguarda Hospital in Milan includes observations from another group of HCV positive patients who received liver transplants between January 1990 and December 2002. They noted a trend for better patient survival in recent years, "but the cumulative probability of developing severe recurrent disease remained unchanged," the authors report. They pinpointed the combination of a female recipient receiving an old graft as a strong risk factor for a severe recurrence.

An accompanying editorial by Marina Berenguer of Hospital La Fe in Valencia, Spain considers the conflicting data from these studies and others that came before and suggests that advanced donor age together with steroid pulse therapy and over immunosuppression can explain differences in outcomes. "The association with worse outcomes in recent years, and the controversy that seems to surround this observation, is likely due to differences in distribution of these variables from study to study, from center to center, and from year to year."

For future studies, she suggests that researchers use large databases to identify trends in liver transplantation, or that they perform studies comparing different management strategies. In the absence of effective antivirals, she concludes, "we are obliged to make sure through a better understanding of factors associated with outcome that we are minimizing harm to patients with our current management strategies."


'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
(Date:12/7/2016)... ... December 07, 2016 , ... The ... its fully redesigned website, which launched October 17, 2016, features comprehensive information regarding ... and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments ...
(Date:12/7/2016)... ... ... The medical profession is well aware that heart attacks do indeed increase ... attacks among 138,602 people recorded a 35% higher number of heart attacks in December ... course–no time of year is a good time for a heart attack! In the ...
(Date:12/7/2016)... ... , ... “The Road To Restoration”: an informative and enlightening book for ... week showing of hands. “The Road To Restoration” is the creation of published author, ... the brass ring that you could reach out for, and grab, on the old ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. This ... share a range of experiences from a cross-section of industries such as financial ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty Infusion ... Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites. ... .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the work we have done, ...
(Date:12/7/2016)... PALO ALTO, Calif. , Dec. 7, 2016 /PRNewswire/ ... announced an update to its previously announced plans to ... to be executed via a tax-free distribution to Varian ... new stand-alone public company that will hold the Imaging ... now expected to be executed by the end of ...
(Date:12/7/2016)... -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), the leader in ... at the BMO Capital Markets Prescriptions for Success Healthcare Conference on ... A live webcast of the presentation will be available ... replay will be available within 48 hours and will be archived ... , ...
Breaking Medicine Technology: